Agilent (A) Receives a Buy from Morgan Stanley
In a report released today, Kallum Titchmarsh from Morgan Stanley maintained a Buy rating on Agilent, with a price target of $180.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Titchmarsh is a 3-star analyst with an average return of 3.7% and a 37.70% success rate. Titchmarsh covers the Healthcare sector, focusing on stocks such as Stevanato Group, Danaher, and GRAIL Inc.
In addition to Morgan Stanley, Agilent also received a Buy from Barclays’s Luke Sergott in a report issued today. However, yesterday, TipRanks – xAI downgraded Agilent (NYSE: A) to a Hold.
Based on Agilent’s latest earnings release for the quarter ending October 31, the company reported a quarterly revenue of $1.86 billion and a net profit of $434 million. In comparison, last year the company earned a revenue of $1.7 billion and had a net profit of $351 million
Based on the recent corporate insider activity of 75 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of A in relation to earlier this year. Most recently, in December 2025, Rodney Gonsalves, the V.P., Corporate Controller of A sold 3,119.00 shares for a total of $483,310.03.
Read More on A:
